Acorai, a Swedish innovator specializing in heart failure management devices, has secured $4.5M in funding from the EIC Fund, Taiwan Medical University, and private backers. The funds will support the completion of clinical trials and the preparation of regulatory filings in the US and Europe, advancing the company’s groundbreaking solutions in cardiac care.
The CAPTURE-HF clinical study, Acorai’s flagship trial, has concluded patient enrollment, involving over 1,600 participants across 20 hospitals in six countries. With FDA Breakthrough Device Designation and collaboration through the TAP Pilot program, the company is on track for regulatory submissions and a potential commercial launch by 2026, aiming to revolutionize non-invasive heart health monitoring.
Looking ahead, an additional $6M has been provisioned by the EIC Fund for future equity financing. Acorai plans to raise further capital in 2025 to support extended clinical validation, secure regulatory approvals, and initiate early commercialization efforts, solidifying its position in the healthcare market.
“We are happy to welcome the EIC Fund as an investor in Acorai and look forward to working closely with the fund as one of Europe’s leading deep tech investors,” said Acorai CEO Filip Peters. “This investment represents another important step toward bringing our solution to the market, with the potential to impact over 60 million heart failure patients worldwide positively.”
